申请人:Love John Christopher
公开号:US20070203189A1
公开(公告)日:2007-08-30
This invention concerns the use of a compound of formula (I′)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C
1-6
alkyl; C
1-6
alkylcarbonyl; C
1-6
alkyloxycarbonyl; aminocarbonyl; C
1-6
alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C
1-4
alkyl substituted piperidinyl, mono- or di(C
1-6
alkyl)amino, aminocarbonyl, mono- or di(C
1-6
alkyl)aminocarbonyl, C
1-6
alkyloxycarbonyl, C
1-6
alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC
1-4
alkyl; cyano; amino; mono- or di(C
1-6
alkyl)aminocarbonyl; C
1-6
alkyloxycarbonyl; C
1-6
alkylcarbonyloxy; aminoS(═O)
2
—; mono- or di(C
1-6
alkyl)aminoS(═O)
2
; —C(═N—R
x
)NR
y
R
z
; Q is optionally substituted C
3-6
cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula
L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12.